President Donald Trump is set to fire FDA Commissioner Marty Makary, The Wall Street Journal reports, citing sources familiar ...

Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to a 95 billion ...

After losing the top spot in March to Johnson & Johnson’s immunology drug Tremfya, AbbVie’s rival med Skyrizi is back as the ...

With an FDA decision date looming for its Duchenne muscular dystrophy (DMD) treatment deramiocel, Capricor Therapeutics has filed a ...

GSK is teaming up with “Modern Family” stars Julie Bowen and Ty Burrell to help get out the messaging: “ask to be sure” about ...

Gilead raised its previous guidance of $800 million in revenues from the long-acting PrEP injectable Yeztugo based on a ...

With its largest-ever acquisition, Angelini gains 24-year-old Catalyst, which was listed on the Nasdaq in 2006. Catalyst ...

Summit Therapeutics' closely watched PD-1xVEGF study surprisingly missed its mark at an interim analysis. | Summit's ...

After a surprise rejection at the beginning of 2026, the FDA has agreed to reconsider a T-cell therapy based on the same ...

Alnylam with an untitled letter over the consumer website for Amvuttra, accusing the biotech | The FDA has hit Alnylam with ...

In this episode of “The Top Line,” Fierce Pharma’s Fraiser Kansteiner sits down with Chris Young, a principal in KPMG’s trade ...

Working with mental health advocates and Mental Health America, the “Generation Fine” project “highlights the unique ...